New medicines for early Alzheimer’s
Largest group of brain and cognitive health medical experts in the UK offer anyone with mild/early Alzheimer’s the opportunity to access two ground-breaking new medicines in late stage clinical trial.
To date, both medicines have demonstrated improvement in previous studies and are “disease modifying” which means that they target the biological processes in the brain which lead to Alzheimer’s rather than simply addressing the symptoms.
Anyone who meets the criteria for either study can apply, and for those who are successfully enrolled it’s completely free for the whole 18 month period.
Dr Emer MacSweeney, medical director at Re:Cognition Health, comments that “this is a very significant opportunity for anyone with memory problems that may be the early stages of Alzheimer’s to receive one of the new generation of medicines up to 3 years before it is generally available”. She continues “some of our highly experienced team of consultants have been involved in the development of these new types of medicines and they are very excited by the potential to slow down progression so that people can live more independently, for longer”
To register for further information for yourself or a relative, simply email email@example.com
About Re:Cognition Health
Re:Cognition Health is the UK’s leading group of brain health and cognitive medical experts. The company has clinics in London, Guildford, Windsor and Buckhurst Hill and supports people with all types of cognitive problems including memory loss, brain injury, stroke, Alzheimer’s, Parkinson’s, other dementias, MS, anxiety and depression, post-traumatic stress, ADHD, autism, and dyslexia
The clinical team includes neurologists, psychiatrists, neuro-psychologists, neuro-radiologists, specialist nurses, neuro-rehabilitation therapists, care of the elderly physicians, and a specialised children’s team. Together the team can provide end to end care from staying healthy, assessment and diagnosis, treatment, therapy, ongoing psychological and care support. Other services include clinical trials for new Alzheimer’s medicines, and medico-legal expertise for people pursuing a brain injury related claim.